Table 4 Changes in headache frequency, migraine frequency, and ASC-12 scores. Change in headache and migraine frequency compares weeks 5–8 after the first erenumab treatment to the 4-week pre-treatment period. Change in ASC-12 scores compares those obtained during the research visit at 8 weeks after the first erenumab treatment to those collected just before the first treatment. ASC-12 = Allodynia Symptom Checklist 12
|  | All Participants (n = 32) | Responders (n = 18) | Non-Responders (n = 14) | p-value (responders vs. non-responders) |
|---|---|---|---|---|
Change in Headache Day Frequency/ 28 days, mean | − 7.1 | −10.1 | − 3.4 | < 0.001 |
Change in Migraine Day Frequency/ 28 days, mean | − 6.9 | − 10.3 | −2.4 | < 0.001 |
Change in ASC-12 scores, mean | − 1.6 | −3.4 | 0.8 | < 0.001 |